Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
| Revenue (TTM) | $70.92M |
| Gross Profit (TTM) | $-268.72M |
| EBITDA | $-385.23M |
| Operating Margin | -82389.00% |
| Return on Equity | -58.10% |
| Return on Assets | -33.30% |
| Revenue/Share (TTM) | $0.79 |
| Book Value | $4.92 |
| Price-to-Book | 4.25 |
| Price-to-Sales (TTM) | 31.87 |
| EV/Revenue | 22.06 |
| EV/EBITDA | -3.18 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 95.80% |
| Shares Outstanding | $110.43M |
| Float | $97.76M |
| % Insiders | 0.14% |
| % Institutions | 111.34% |
Volatility is currently expanding
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.
Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results.
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript
Viridian Therapeutics is positioned to transition from late-stage biotech to commercial rare disease player with its TED franchise. Veligrotug's pivotal Phase 3 data in active and chronic TED and an FDA PDUFA date of June 30, 2026, create a near-term commercial entry point. Elegrobart, a subcutaneous follow-on asset, targets market expansion by reducing treatment barriers and is planned for a Q1 2027 BLA submission.
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
OTTAWA, June 09, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) announces that diamond drilling has commenced at its Kraken Copper-Nickel-Cobalt Project in Labrador, with the first drill now turning on the initial hole of the Company's fully funded 2026 exploration program. The 2026 program is expected to consist of 50 diamond drill holes designed to systematically infill between widely spaced drill holes completed along the five-kilometre-long Main Zone conductive corridor, where mineralization has been intersected in holes spaced up to one kilometre apart.
OTTAWA, Ontario, June 05, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) is advancing plans to target high-grade copper-rich zones identified within the Kraken magmatic sulphide system in Labrador, where drilling in 2024 intersected copper grades up to 4.15% Cu (see news release dated November 26, 2024). The Company's recently announced 50-hole drill program will provide the scale and flexibility required to systematically follow up on multiple copper-rich zones identified within the broader Kraken system.
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY Goldman Sachs 47th Annual Global Healthcare.
OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Viridian Metals (CSE: VRDN) (“Viridian” or the “Company”) will commence a minimum 50-hole drill program in early June at its Kraken Copper-Nickel Project in Labrador, aimed at defining the scope of copper-nickel sulphide mineralization traced over approximately 5 kilometres along the Main Zone. Previous drilling intersected mineralization at roughly 1-kilometre spacing, outlining the scale of the Main Zone discovery.
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its upsized underwritten publ.
